According to a new report published by Reports Monitor titled, “Epigenetics Market by Product, Application, Technology and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the epigenetics market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025.
Epigenetics is a stream of genetics that encompasses investigation of the cellular and physiological trait modifications caused due to any ecological or external factors. Epigenetics causes turning off and on of some of the genes which that eventually determines which cell should terminally differentiate to end up as skin cells or river cells etc. sometimes they may provoke diseases like cancer.
Various factors such as rising predominance of cancer, enhanced funding & aids for research and development activities and strong government initiatives propels the growth of the epigenetics market. Surging collaborations between biotech and pharma companies and various contract research organizations boost the market growth. For instance, the National Institute of Health funds epigenetics research through common fund ecogenomics programmes that are vigorously backing new epigenetic research worldwide. However, lack of skilled personnel and high cost of instruments may roadblock the further expansion of the market. Presence of giant players, extensive R&D, availability of findings, favourable government activities and rising incidences of various diseases contributes to the growth of the epigenetics market in North America.
The global epigenetics market is segmented on the basis of product, application, technology, end-user and region. Based on product the market is broadly segmented into kits, reagents, enzymes, instruments and consumables and bioinformatics tools. Application wise market is separated into oncology, developmental biology, metabolic diseases, cardiovascular diseases, and immunology. Depending upon technology, the market is divided into DNA methylation, histone modification. Based on end-user segment the market is categorized into academic & research institutes, pharmaceutical & biotechnological companies and contract research organizations.
The prominent market players running in the market are Sigma-Aldrich Corporation, QIAGEN N.V Thermo Fisher Scientific, Inc., Novartis AG, Abcam Plc., Merck & Co., New England Biolabs, Inc., Illumina, Epizyme Inc. and Active Motif. Players are implementing various growth strategies in the market to gain a competitive edge. Qiagen NV announced acquisition of Ingenuity Systems Inc. in 2013. Ingenuity Systems Inc. is provider of software solutions for efficient and precise analysis and interpretation of genomic data.
In December 2017, Roche and Ignyta, Inc. declared that they have entered into a definitive merger agreement. Ignyta’s a selective CNS-active tyrosine-kinase inhibitor being developed for tumours which harbor ROS1 or NTRK fusions and investigational medicine entrectinib will be fully acquired by Roche under this agreement so as to enhance the Roche’s product portfolio of oncology medicines.
About Garner Insights:
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.